Handok Inc
Handok Inc's capital structure is characterized by a debt-to-equity ratio of 1.37, indicating a relatively high level of leverage. The company's liquidity position is assessed as medium, with a current ratio of 0.77, suggesting that it may face challenges in meeting its short-term obligations. The company's price-to-book ratio is 0.47, and its price-to-tangible-book ratio is also 0.47, indicating that the market value is significantly lower than the book value of its tangible assets. In terms of profitability, Handok Inc reported a net income of -2,153,006,040 KRW, resulting in a negative return on equity of -0.78% and a negative return on assets of -0.27%. These figures are below the industry median for profitability metrics, indicating that the company is underperforming relative to its peers in the Pharmaceuticals industry. Handok Inc's revenue is primarily concentrated in the pharmaceuticals segment, with a significant portion derived from its core products such as Amaryl, Tritace, Teveten, and Triapin. The company also has a real estate rental business, but the financial data does not provide a breakdown of revenue by segment or geographic region. The company's growth trajectory is uncertain, as it reported a net loss in the latest financial period. The outlook for the current fiscal year and the next fiscal year is not provided, but the negative net income suggests that the company may face challenges in achieving revenue growth. The company's operating cash flow is 3,982,491,150 KRW, and its free cash flow is 2,483,760,520 KRW, indicating that it generates positive cash flow from operations. The risk assessment for Handok Inc indicates a medium level of liquidity risk and a low level of dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which could impact its ability to meet long-term obligations. The company's dilution potential is low, as the number of shares outstanding is the same for both basic and diluted shares. Recent events and filings for Handok Inc include a name change from Handok Pharmaceuticals Co., LTD to Handok Inc on July 26, 2013. The company's financial performance has been impacted by a net loss, and its liquidity position is a concern. The company's capital expenditure is negative, indicating that it is generating more cash from operations than it is spending on capital investments.
Business. Handok Inc is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals, including products for diabetes, hypertension, cardiovascular diseases, and other conditions, as well as over-the-counter pharmaceuticals, healthcare products, medical devices, diagnostic reagents, vaccines, and real estate rental business.
Classification. Handok Inc is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry with a confidence level of 0.92.
- Handok Inc has a high debt-to-equity ratio of 1.37, indicating a significant level of leverage.
- The company reported a net loss of 2,153,006,040 KRW, resulting in negative returns on equity and assets.
- Handok Inc's liquidity position is medium, with a current ratio of 0.77, suggesting potential challenges in meeting short-term obligations.
- The company's market price is 9,950 KRW, with a market cap of 129,260,012,200 KRW, and a price-to-book ratio of 0.47.
- The company's capital expenditure is negative, indicating that it is generating more cash from operations than it is spending on capital investments.
- # RATIONALES
- margin_outlook_rationale: The company's negative net income and low profitability metrics suggest a challenging margin outlook.
- rd_outlook_rationale: The company's financial data does not provide specific information on research and development expenditures or outlook.
- Net cash is negative after subtracting total debt.